We use cookies to ensure that we give you the best experience on our website. Read privacy policies.
Insilico Medicine, a developer of artificial intelligence tools for drug discovery, has mapped out its process for making an experimental drug for idiopathic pulmonary fibrosis (IPF).
This publication outlines the progression of what the company claims to be the first AI-generated and AI-discovered drug, now advancing to Phase II clinical trials.
Published in Nature Biotechnology, the paper details the entire development process of INS018_055. This drug candidate, aimed at treating idiopathic pulmonary fibrosis, an uncommon yet aggressive lung disease, was identified using Insilico's AI platform. The document unveils the underlying experimental data and provides insights into the preclinical and clinical assessments of this potentially groundbreaking TNIK inhibitor, conceived and designed through generative AI.
Insilico Medicine unveils first AI-generated and AI-discovered drug in new paper
Thank you for subscribing!